Radiation Oncology

Radiation oncology is a medical specialty that uses radiation therapy to treat cancer. The radiation therapy channel covers all aspects of radiation oncology technology. Radiation therapy includes linear accelerators (LINAC), proton therapybrachytherapyimage guided radiation therapy (IGRT)focused ultrasoundstereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), treatment planning systems and tomotherapy.

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017

An estimated one in seven American men will be affected by...

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017

In the battle against metastatic ...

News | Radiation Oncology | June 12, 2017

The alliance will study the feasibility of using CRnR’s converging x-ray lens technology as an effective...

stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017

The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of...

Sponsored Content | Case Study | Radiation Therapy | June 08, 2017

Stereotactic body radiation therapy (SBRT) employs significantly higher per fraction radiation doses than...

pediatric imaging
News | Radiation Oncology | June 08, 2017

In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure...

Feature | Radiation Therapy | June 07, 2017 | By Melinda Taschetta-Millane

According to the National Institutes of Health (NIH), precision-based medicine is an emerging approach for disease...

Gamma Knife
News | Radiation Oncology | June 05, 2017

Up to 45 percent of all cancer patients develop brain...

ASTRO Opposes White House Fiscal Year 2018 Budget for Cancer Research and Care
News | Radiation Therapy | May 31, 2017

May 31, 2017 — The American Society for Radiation Oncology (ASTRO) released a statement last week strongly opposing...

Research Shows Breast Cancer Surgery Marker Associated With Smaller Radiation Volume
News | Radiation Therapy | May 30, 2017

May 30, 2017 — Patients who were implanted with the BioZorb 3-D bioabsorbable marker during their...

Royal College of Radiologists Publishes New Guidance on Interventional Oncology
News | Interventional Radiology | May 25, 2017

May 25, 2017 —The Royal College of Radiologists (RCR) has published a new edition of its guidance on the application...

Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017

May 24, 2017 — A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has...

News | Image Guided Radiation Therapy (IGRT) | May 24, 2017

May 24, 2017 — The University Medical Centre (UMC) Utrecht in the Netherlands recently treated the first patient as...

First Patient Treated With Pencil Beam Scanning at Institute Curie Proton Therapy Center
News | Proton Therapy | May 23, 2017

May 23, 2017 — IBA announced that the first patient has been treated with pencil beam scanning (PBS) technology at...

ASTRO's 59th Annual Meeting Will Explore Art and Science of Radiation Oncology
News | Radiation Therapy | May 19, 2017

May 19, 2017 — Registration has opened for the 59th Annual Meeting of the American Society for Radiation Oncology (...

MidMichigan Medical Center to Install RAD Technology Temporary Radiotherapy Vault
News | Radiation Therapy | May 17, 2017

May 17, 2017 — RAD Technology Medical Systems and MidMichigan Medical Center — Alpena broke ground the end of March...

News | Radiation Therapy | May 16, 2017

May 16, 2017 — Proton International announced the successful financing of a new state-of-the-art...

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017

May 15, 2017 — Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be...

Proton Monte Carlo Dose Calculation Now Part of RayStation Treatment Planning
News | Treatment Planning | May 15, 2017

May 15, 2017 — RaySearch demonstrated a new Monte Carlo dose planning feature for...